- Our LinkedIn Page
- Our Twitter Feed
- Our Facebook Page
- Newsletter Subscribe to our e-newsletter. Current Issue
- Our Flickr Feed
- Our YouTube Feed
Authors
- Abigail Hirsch
- Alan Eisenberg
- BIOtechNOW Editor
- Bruce Dale
- Celia Economides
- Colleen Lerro
- David Thomas, CFA
- George Goodno
- George MacDougall
- Jason Corum
- Jeff Joseph
- Jim Greenwood
- Karen Batra
- Kelly Cappio
- Lila Feisee
- Matt Carr
- Nathan Schock
- Paul Winters
- Paulina Ibarra
- Robbi Lycett
- Roy Zwahlen
- Sarah Sneeringer
- Sondra Behan
- Stephanie Fischer
- Stephen Marmaras
- Tracy Cooley
Tag Archives: BIO
BIO’s Intellectual Property Counsels Committee Seattle Meeting Topics
Join us for BIO’s Intellectual Property Counsels Committee Meeting in Seattle April 13-15. You can find the session topics below. Whose Rights Are They, Anyway? Implications from and a Discussion on Stanford v. Roche The pending Supreme Court review of Stanford v. Roche has brought out multiple perspectives on the disposition of ownership rights in federally funded inventions under Bayh-Dole. This session will explore the different interpretations of the Act’s provisions, and their practical implications Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: Bill and Melinda Gates Foundation, BIO, biosimilars, biotechnology, Brazil, China, double patenting, emerging markets, Erik Iverson, ethics, Gates Foundation, humanitarian, in house IP attorneys, India, Intellctual Property, Intellectual Property Counsels, IP Counsels' Committee, Korea, Myriad, Patent Agents, research collaborations, Seattle, Stanford v. Roche
Tags: Bill and Melinda Gates Foundation, BIO, biosimilars, biotechnology, Brazil, China, double patenting, emerging markets, Erik Iverson, ethics, Gates Foundation, humanitarian, in house IP attorneys, India, Intellctual Property, Intellectual Property Counsels, IP Counsels' Committee, Korea, Myriad, Patent Agents, research collaborations, Seattle, Stanford v. Roche
Biotech, Gates Foundation, and Global Health
Great interview by Gene Quinn with Erik Iverson, Associate General Counsel with the Bill & Melinda Gates Foundation. A summary article is on BIOtech Now and the full interview can be found on IPWatchdog.com. Highlights: Iverson told me in no uncertain terms, “[A] fundamental premise at the foundation is that we absolutely respect intellectual property rights. We recognize their importance and we certainly recognize the importance of companies and their involvement in developing products and having Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: Bill & Melinda Gates Foundation, Bill Gates, BIO, biotechnology, developing countries, Erik Iverson, Gene Quinn, Global Health, global health, humanitaria, humanitarian, Intellectual Property, IPWatchdog, life science, Neglected Diseases, patent
Tags: Bill & Melinda Gates Foundation, Bill Gates, BIO, biotechnology, developing countries, Erik Iverson, Gene Quinn, Global Health, global health, humanitaria, humanitarian, Intellectual Property, IPWatchdog, life science, Neglected Diseases, patent
Patent Reform Bill good for Biotech
Patent Reform Passes the Senate and Moves to the House Posted by Roy Zwahlen, manager of intellectual property and technology transfer policy at BIO. On March 8th, the Senate approved the America Invents Act (S. 23) by an overwhelming vote of 95-5. BIO supports this bipartisan, consensus-oriented bill, formerly known as the Patent Reform Act of 2011. Once enacted into law, it will strengthen and improve our nation’s patent system, spurring innovation and job creation. Patents are often Read More >
Patently BIOtech
1 Comment
Email This Post
Tags: America Invents Act, best mode, BIO, BIOTECH, Biotechnology Industry, bipartisan, False marking, false patent marking, First inventor to file, First to file, first to invent, Grassley, Leahy, Patent and Trademark Office, Patent Reform, PTO, PTO Reexaminations, Senate Judiciary Comm, USPTO
Tags: America Invents Act, best mode, BIO, BIOTECH, Biotechnology Industry, bipartisan, False marking, false patent marking, First inventor to file, First to file, first to invent, Grassley, Leahy, Patent and Trademark Office, Patent Reform, PTO, PTO Reexaminations, Senate Judiciary Comm, USPTO
BIO Hails Senate Passage of America Invents Act
BIO Hails Senate Passage of America Invents Act Bipartisan, consensus-oriented approach will strengthen nation’s patent system and spur innovation, job creation Washington, D.C. (March 8, 2011) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on the passage today of the America Invents Act (S. 23) by the U.S. Senate: “BIO commends the Senate for its overwhelming passage of the America Invents Act by a vote of 95-5. We appreciate Read More >
Biofuels Digest, BIO Launch Spring 2011 Bioenergy Business Outlook Survey
Biofuels Digest and the Biotechnology Industry Organization (BIO) invite the industry to take part in the Spring 2011 Bioenergy Business Outlook Survey. The survey examines growth expectations and opportunities from a company, national and organizational point of view. It also examines the role of research, government policy, finance, and research and market partners in creating opportunities or barriers to the growth of green jobs, energy security and reductions in greenhouse gas emissions. The survey is Read More >
